Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCR-T targeting NY-ESO-1
- Development stage
- Preclinical
- Lead developer
- Beijing Yongtai Ruike Biotechnology
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TCR-T targeting NY-ESO-1 is a preclinical-stage T cell receptor-engineered T cell (TCR-T) therapy being developed by Beijing Yongtai Ruike Biotechnology (a subsidiary of Beijing Yongtai). The therapy utilizes autologous T cells genetically modified to express T-cell receptors (TCRs) that specifically recognize NY-ESO-1 (New York Esophageal Squamous Cell Carcinoma 1), a cancer-testis antigen (CTA) frequently expressed in various malignancies but absent in normal adult somatic tissues. By re-infusing these engineered cells into the patient, the therapy aims to induce targeted destruction of NY-ESO-1-expressing tumor cells. The program is currently being evaluated for the treatment of solid tumors, including clear cell renal carcinoma.
- Other names
- NY-ESO-1 TCR-TNY-ESO1 TCR-TNY-ESO 1 TCR-TNY-ESO-1-specific TCR-T cell therapyNY-ESO1-specific TCR-T cell therapyNY-ESO 1-specific TCR-T cell therapyTCR-T-NY-ESO-1TCR-T-NY-ESO1TCR-T-NY-ESO 1
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on TCR-T targeting NY-ESO-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCR-T targeting NY-ESO-1.